Skip to main content
NCBI home page
Gut logoLink to Gut
. 1993 Oct;34(10):1319–1326. doi: 10.1136/gut.34.10.1319

Prospective multicentre study of risk factors associated with delayed healing of recurrent duodenal ulcers (RUDER). RUDER Study Group.

D Armstrong 1, R Arnold 1, M Classen 1, M Fischer 1, H Goebell 1, A L Blum 1
PMCID: PMC1374534  PMID: 8244095

Abstract

Risk factors for delayed duodenal ulcer healing during treatment with ranitidine (300 mg daily) were examined in a multicentre German study of 1923 patients with endoscopically proved, recurrent duodenal ulceration. Healing rates, per protocol, were 39.5% at two weeks, 70.9% at four weeks, and 93.2% at eight weeks. Prospective testing of five, predefined risk factors indicated that smoking (p = 0.0039) was associated with a decreased healing rate at two weeks. Frequent prior recurrence (p = 0.464), a heavy physical workload (p = 0.145), and psychological stress (p = 0.062) were not associated with a decreased healing rate and there were too few patients at risk to allow assessment of the effect of regular NSAID intake. Exploratory analysis identified prior slow healing, a large ulcer, multiple ulcers, and prior ulcer complications, in addition to smoking, as markers of slow healing. In the absence of these risk factors, the mean healing time was 3.3 weeks (95% confidence interval 3.0, 3.5), rising to 3.7 weeks (3.5, 3.9) for one, 4.4 weeks (4.1, 4.7) for two, and 5.1 weeks (4.5, 5.6) for three to five risk factors. Delayed duodenal ulcer healing is associated with multiple factors whose effect is cumulative; for patients with two or more of five easily identified risk factors, more than four weeks' treatment with a histamine H2 receptor antagonist is required to achieve ulcer healing.

Full text

PDF
1319

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Bardhan K. D. Refractory duodenal ulcer. Gut. 1984 Jul;25(7):711–717. doi: 10.1136/gut.25.7.711. [DOI] [PMC free article] [PubMed] [Google Scholar]
  2. Bauerfeind P., Cilluffo T., Fimmel C. J., Emde C., von Ritter C., Kohler W., Gugler R., Gasser T., Blum A. L. Does smoking interfere with the effect of histamine H2-receptor antagonists on intragastric acidity in man? Gut. 1987 May;28(5):549–556. doi: 10.1136/gut.28.5.549. [DOI] [PMC free article] [PubMed] [Google Scholar]
  3. Bertschinger P., Lacher G., Aenishänslin W., Baerlocher C., Bernoulli R., Egger G., Eisner M., Fasel F., Fehr H. R., Fumagalli I. Presenting characteristics of patients with duodenal ulcer and outcome of medical treatment in controlled clinical trials using cimetidine and diethylamine persilate to treat ulcer attack and diethylamine persilate and placebo to prevent relapses. Digestion. 1987;36(3):148–161. doi: 10.1159/000199412. [DOI] [PubMed] [Google Scholar]
  4. Brunner H., Dittrich H., Kratochvil P., Brandstätter G., Hentschel E., Schütze K., Tragl K. H., Kern H., Löffelmann K., Zeiler H. Treatment of duodenal ulcer with pirenzepine and cimetidine. Gut. 1984 Feb;25(2):206–210. doi: 10.1136/gut.25.2.206. [DOI] [PMC free article] [PubMed] [Google Scholar]
  5. CLARKE C. A., EDWARDS J. W., HADDOCK D. R., HOWEL-EVANS A. W., MCCONNELL R. B., SHEPPARD P. M. ABO blood groups and secretor character in duodenal ulcer; population and sibship studies. Br Med J. 1956 Sep 29;2(4995):725–731. doi: 10.1136/bmj.2.4995.725. [DOI] [PMC free article] [PubMed] [Google Scholar]
  6. Gitlin N., McCullough A. J., Smith J. L., Mantell G., Berman R. A multicenter, double-blind, randomized, placebo-controlled comparison of nocturnal and twice-a-day famotidine in the treatment of active duodenal ulcer disease. Gastroenterology. 1987 Jan;92(1):48–53. doi: 10.1016/0016-5085(87)90838-9. [DOI] [PubMed] [Google Scholar]
  7. Hancock L., Walsh R., Henry D. A., Redman S., Sanson-Fisher R. Drug use in Australia: a community prevalence study. Med J Aust. 1992 Jun 1;156(11):759–764. doi: 10.5694/j.1326-5377.1992.tb121556.x. [DOI] [PubMed] [Google Scholar]
  8. Hasan M., Sircus W. The factors determining success or failure of cimetidine treatment of peptic ulcer. J Clin Gastroenterol. 1981 Sep;3(3):225–229. doi: 10.1097/00004836-198109000-00005. [DOI] [PubMed] [Google Scholar]
  9. Holtmann G., Armstrong D., Pöppel E., Bauerfeind A., Goebell H., Arnold R., Classen M., Witzel L., Fischer M., Heinisch M. Influence of stress on the healing and relapse of duodenal ulcers. A prospective, multicenter trial of 2109 patients with recurrent duodenal ulceration treated with ranitidine. RUDER Study Group. Scand J Gastroenterol. 1992 Nov;27(11):917–923. doi: 10.3109/00365529209000163. [DOI] [PubMed] [Google Scholar]
  10. Ippoliti A. F., Sturdevant R. A., Isenberg J. I., Binder M., Camacho R., Cano R., Cooney C., Kline M. M., Koretz R. L., Meyer J. H. Cimetidine versus intensive antacid therapy for duodenal ulcer: a multicenter trial. Gastroenterology. 1978 Feb;74(2 Pt 2):393–395. [PubMed] [Google Scholar]
  11. Korman M. G., Hansky J., Merrett A. C., Schmidt G. T. Ranitidine in duodenal ulcer: incidence of healing and effect of smoking. Dig Dis Sci. 1982 Aug;27(8):712–715. doi: 10.1007/BF01393766. [DOI] [PubMed] [Google Scholar]
  12. Lam S. K., Lai C. L., Lee L. N., Fok K. H., Ng M. M., Siu K. F. Factors influencing healing of duodenal ulcer. Control of nocturnal secretion by H2 blockade and characteristics of patients who failed to heal. Dig Dis Sci. 1985 Jan;30(1):45–51. doi: 10.1007/BF01318370. [DOI] [PubMed] [Google Scholar]
  13. Lee F. I., Reed P. I., Crowe J. P., McIsaac R. L., Wood J. R. Acute treatment of duodenal ulcer: a multicentre study to compare ranitidine 150 mg twice daily with ranitidine 300 mg once at night. Gut. 1986 Sep;27(9):1091–1095. doi: 10.1136/gut.27.9.1091. [DOI] [PMC free article] [PubMed] [Google Scholar]
  14. Marshall B. J., Goodwin C. S., Warren J. R., Murray R., Blincow E. D., Blackbourn S. J., Phillips M., Waters T. E., Sanderson C. R. Prospective double-blind trial of duodenal ulcer relapse after eradication of Campylobacter pylori. Lancet. 1988 Dec 24;2(8626-8627):1437–1442. doi: 10.1016/s0140-6736(88)90929-4. [DOI] [PubMed] [Google Scholar]
  15. Mason J. B., Moshal M. G., Naidoo V., Schlemmer L. The effect of stressful life situations on the healing of duodenal ulceration. S Afr Med J. 1981 Nov 7;60(19):734–737. [PubMed] [Google Scholar]
  16. Massarrat S., Eisenmann A. Factors affecting the healing rate of duodenal and pyloric ulcers with low-dose antacid treatment. Gut. 1981 Feb;22(2):97–102. doi: 10.1136/gut.22.2.97. [DOI] [PMC free article] [PubMed] [Google Scholar]
  17. Massarrat S., Müller H. G., Schmitz-Moormann P. Risk factors for healing of duodenal ulcer under antacid treatment: do ulcer patients need individual treatment? Gut. 1988 Mar;29(3):291–297. doi: 10.1136/gut.29.3.291. [DOI] [PMC free article] [PubMed] [Google Scholar]
  18. Murthy S. N., Dinoso V. P., Jr, Clearfield H. R., Chey W. Y. Serial pH changes in the duodenal bulb during smoking. Gastroenterology. 1978 Jul;75(1):1–4. [PubMed] [Google Scholar]
  19. Müller-Lissner S. A. Bile reflux is increased in cigarette smokers. Gastroenterology. 1986 May;90(5 Pt 1):1205–1209. doi: 10.1016/0016-5085(86)90386-0. [DOI] [PubMed] [Google Scholar]
  20. Okada M., Yao T., Maeda K., Yamamoto T., Saigenji K., Okada Y., Sakamoto K., Tanaka K. Predictors of duodenal ulcer healing during treatment with cimetidine. Gut. 1990 Jul;31(7):758–762. doi: 10.1136/gut.31.7.758. [DOI] [PMC free article] [PubMed] [Google Scholar]
  21. Reynolds J. C. Famotidine therapy for active duodenal ulcers. A multivariate analysis of factors affecting early healing. Ann Intern Med. 1989 Jul 1;111(1):7–14. doi: 10.7326/0003-4819-111-1-7. [DOI] [PubMed] [Google Scholar]
  22. Samloff I. M., Liebman W. M., Panitch N. M. Serum group I pepsinogens by radioimmunoassay in control subjects and patients with peptic ulcer. Gastroenterology. 1975 Jul;69(1):83–90. [PubMed] [Google Scholar]
  23. Sonnenberg A. Dietary salt and gastric ulcer. Gut. 1986 Oct;27(10):1138–1142. doi: 10.1136/gut.27.10.1138. [DOI] [PMC free article] [PubMed] [Google Scholar]
  24. Sonnenberg A., Müller-Lissner S. A., Vogel E., Schmid P., Gonvers J. J., Peter P., Strohmeyer G., Blum A. L. Predictors of duodenal ulcer healing and relapse. Gastroenterology. 1981 Dec;81(6):1061–1067. [PubMed] [Google Scholar]
  25. Stadler P., Armstrong D., Margalith D., Saraga E., Stolte M., Lualdi P., Mautone G., Blum A. L. Diclofenac delays healing of gastroduodenal mucosal lesions. Double-blind, placebo-controlled endoscopic study in healthy volunteers. Dig Dis Sci. 1991 May;36(5):594–600. doi: 10.1007/BF01297025. [DOI] [PubMed] [Google Scholar]
  26. Van Deventer G. M., Schneidman D., Walsh J. H. Sucralfate and cimetidine as single agents and in combination for treatment of active duodenal ulcers. A double-blind, placebo-controlled trial. Am J Med. 1985 Aug 30;79(2C):39–44. doi: 10.1016/0002-9343(85)90571-6. [DOI] [PubMed] [Google Scholar]

Articles from Gut are provided here courtesy of BMJ Publishing Group

RESOURCES